Regulation Versus Practice--the Impact of Accessibility on the Use of Specialist Health Care in Norway
Overview
Public Health
Authors
Affiliations
In Norway specialized health services are provided both by public hospitals and by privately practicing specialists who have a contract with the public sector. A patient's co-payment is the same irrespective of the type of provider he visits. The ambition of equity in the allocation of medical care is high among all political parties. The instruments for auditing whether these goals are fulfilled are not equally ambitious. The objective of the present study is to explore whether laws and regulations that govern the allocation of specialist health care resources in fact are fulfilled. Panel data from the Survey of Living Conditions are merged with data on capacity and spatial access to primary and specialist care. We find that accessibility and socio-economic variables play a considerable role in determining both the probability of at least one visit and the number of visits to a private specialist. A person with a higher university degree living in a municipality with the highest value of the geographical accessibility index has a 46%-points higher probability of at least one visit to a private specialist compared with a person with junior high living in a municipality with the lowest value of the accessibility index. With regard to visits to a hospital outpatient department these variables are not found to have significant effects. We conclude that public ambitions and regulations are fulfilled for specialist services provided by public hospitals. With regard to the provision of services provided by publicly financed private specialists we find a discrepancy between public goals and surveyed practice.
Dysphagia Care and Management in Rehabilitation: A National Survey.
Speyer R, Sandbekkbraten A, Rosseland I, Moore J J Clin Med. 2022; 11(19).
PMID: 36233598 PMC: 9571108. DOI: 10.3390/jcm11195730.
Health Inequalities in Older Norwegians and the Mediating Role of Social Networks.
Adhikari N, Uddin S Int J Aging Hum Dev. 2022; 97(2):202-228.
PMID: 35837689 PMC: 10291358. DOI: 10.1177/00914150221112281.
BOe T, Hysing M, Askeland K, Skogen J, Heradstveit O Health Serv Insights. 2021; 14:11786329211055302.
PMID: 34916801 PMC: 8669118. DOI: 10.1177/11786329211055302.
Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors.
Binde C, Tvete I, Klemp M Parkinsons Dis. 2021; 2021:9952743.
PMID: 34306611 PMC: 8270692. DOI: 10.1155/2021/9952743.
Klitkou S, Iversen T, Stensvold H, Ronnestad A BMC Health Serv Res. 2017; 17(1):571.
PMID: 28818072 PMC: 5561635. DOI: 10.1186/s12913-017-2498-3.